Volcano Therapeutics, Inc. to Acquire JOMED, Inc.'s Global Intravascular Ultrasound (IVUS) and Functional Measurement (FM) Businesses

Volcano Therapeutics, Inc. announced today that it has signed a letter of intent to acquire JOMED's global IVUS and Functional Measurement businesses. Volcano Therapeutics is focused on the discovery, development and commercialization of products for the detection and treatment of atherosclerosis and vulnerable plaques located in the coronary and peripheral arteries.

Scott Huennekens, President & CEO of Volcano Therapeutics, noted, "Volcano is focused on providing interventional cardiologists and the medical community advanced technologies to better understand the development and progression of atherosclerosis and vulnerable plaques. The addition of JOMED's state-of-the-art intravascular ultrasound imaging systems is exceptionally synergistic with Volcano's Virtual Histology(TM) IVUS system, recently demonstrated at the International Paris Course on Revascularization.

Volcano's intravascular thermography catheter products will integrate well with the pressure catheter and flow wire interventional products of JOMED's Functional Measurement business." Mr. Huennekens further stated, "This acquisition is consistent with Volcano's vision and strategy to provide interventional cardiologists clinically relevant information to direct specific therapies that will significantly improve clinical outcomes." Lastly, Mr. Huennekens added, "We are excited to employ the 400+ IVUS and FM business unit employees that have successfully built these businesses and look forward to working with them to further build on this success in the months and years ahead."

Olav Bergheim, Volcano's Chairman of the Board, commented, "The combination of the established IVUS and Functional Measurement products with Volcano's emerging technologies thermography and Virtual Histology(TM) IVUS position Volcano as a leader in the diagnosis of atherosclerosis." He added, "With the recent clinical successes of drug eluting stents we see a tremendous opportunity to provide clinicians additional information to justify the use of drug eluting stents and improve their clinical utility. Additionally, this acquisition uniquely positions Volcano to lead the effort to diagnose and treat vulnerable plaques in the coronary arteries. The diagnosis and treatment of vulnerable plaques is projected to be a multi-billion dollar market."

About Volcano

Volcano Therapeutics, Inc., is a privately held medical device company with headquarters in Laguna Hills, CA and European headquarters in Brussels, Belgium. Volcano Therapeutics, Inc., founded in 2001, is focused on the discovery, development and commercialization of products for the detection and treatment of atherosclerosis and vulnerable plaques in the coronary arteries and peripheral vascular system. Currently under development are technologies that could be potentially useful in detecting and treating patients who are at risk for developing plaque rupture and subsequent adverse cardiac events. For more information, please visit www.volcanotherapeutics.com .

SOURCE: Volcano Therapeutics, Inc.

CONTACT: Scott Huennekens,

President & CEO, or

Vince Burgess,

Vice President of Marketing, Business Development,

both of Volcano Therapeutics, Inc.,

+1-949-582-3435, or fax, +1-949-582-3365

Web site: http://www.volcanotherapeutics.com

--Distributed by AsiaNet (www.asianetnews.net)--

• ข่าวVolcano Therapeutics
• ข่าวo:heal
• ข่าวo:asn
• ข่าวen
• ข่าวo:in